

Season's Greetings & Happy Holidays wishes Immunovia



Dear Shareholder,

The past year marked an important milestone for Immunovia with the first sales of IMMray™ PanCan-d in the United States. This exciting development means Immunovia can now start to realize its vision of revolutionizing blood-based diagnostics to enable increased cancer survival rates.

While our first sales are an obvious highlight for Immunovia, there are a number of other important events we can look back on that contributed to this success. Amongst these was CLIA certification in August of the Immunovia, Inc. laboratory in Marlborough, Mass., in the US. This achievement enabled Immunovia Inc. our US subsidiary, to commence sales of IMMray™ PanCan-d.

Another highlight for Immunovia were the positive results in March from the blinded clinical evaluation of IMMray™ PanCan-d. These results paved the way for CLIA certification and confirmed the potential benefits of IMMray™ PanCan-d as a diagnostic tool for the early detection of pancreatic cancer.

This year also saw a significant increase in awareness in the US of Immunovia's work and IMMray™ PanCan-d, in particular. In September, the US Pancreatic Cancer Action Network undertook a widespread communication effort highlighting IMMray™ PanCan-d as the first-ever blood test specific for pancreatic cancer. This was followed in December by Immunovia, Inc.'s Medical Director Dr. Thomas King's appearance as a keynote speaker at the National Cancer Institute's Pancreatic Cancer Detection Consortium Steering Committee Meeting.

Covid-19 continued to present challenges for Immunovia just as it has for so many parts of our society. The ongoing pandemic delayed CLIA certification and impacted on the speed at which IMMray™ PanCan-d could be rolled out to patients. The real or imagined restrictions in access to healthcare for many people as a result of the pandemic has highlighted the importance of early cancer detection.

It goes without saying that all of the achievements of the past year are only made possible by the efforts of the leadership and staff at Immunovia AB and Immunovia, Inc. This will be the last time I send a Christmas greeting as CEO and I would like to take the opportunity to say what a pleasure it has been for me to work with such committed professionals.

We hope you look forward to 2022 as much as we do at Immunovia.

Happy Holidays!

Patrik Dahlen

CEO, Immunovia AB

Lund, December 23, 2021